Shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have received an average rating of "Buy" from the six brokerages that are covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $24.67.
Several brokerages have recently commented on CAPR. Oppenheimer restated an "outperform" rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. Maxim Group raised their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. Cantor Fitzgerald restated an "overweight" rating and issued a $8.00 target price on shares of Capricor Therapeutics in a research note on Friday, September 20th. Finally, Piper Sandler assumed coverage on Capricor Therapeutics in a research note on Monday, October 21st. They set an "overweight" rating and a $35.00 price target for the company.
Check Out Our Latest Stock Analysis on Capricor Therapeutics
Shares of Capricor Therapeutics stock opened at $18.45 on Wednesday. The business has a 50-day moving average price of $12.95 and a two-hundred day moving average price of $7.75. Capricor Therapeutics has a 1-year low of $2.68 and a 1-year high of $23.40. The company has a market cap of $837.74 million, a P/E ratio of -19.84 and a beta of 4.00.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). The business had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. Equities research analysts forecast that Capricor Therapeutics will post -1.17 EPS for the current fiscal year.
In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the company's stock in a transaction on Friday, September 20th. The shares were purchased at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the transaction, the insider now directly owns 7,090,351 shares in the company, valued at $38,004,281.36. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 12.00% of the company's stock.
Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock worth $9,274,000 after buying an additional 200,499 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock worth $656,000 after buying an additional 84,350 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Capricor Therapeutics in the 2nd quarter worth approximately $426,000. Bank of New York Mellon Corp raised its holdings in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock worth $381,000 after purchasing an additional 9,040 shares during the period. Finally, Oppenheimer & Co. Inc. raised its holdings in shares of Capricor Therapeutics by 25.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company's stock worth $1,040,000 after purchasing an additional 13,762 shares during the period. Institutional investors own 21.68% of the company's stock.
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.